1–10 of 89 results for AMD-Non-Neovascular
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023
The PRIMA Bionic Vision System in Patients With Geographic Atrophy
Lisa C. Olmos de Koo, MD, MBA
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Ellipsoid Zone Integrity Preservation and Characterization of Ellipsoid Zone Integrity Features in the GATHER 1 Phase 2/3 Study
Justis P. Ehlers, MD, FASRS
Intravitreal Avacincaptad Pegol in Geographic Atrophy: Post-Hoc Analysis of Vision Loss From the GATHER Clinical Program
Carl J Danzig, MD
Retinal Tissue Preservation With Intravitreal Pegcetacoplan in Patients With Geographic Atrophy
Sunir J. Garg, MD, FACS, FASRS
Effect of Pegcetacoplan on Photoreceptor and Retinal Pigment Epithelium Integrity in Geographic Atrophy in the Phase 3 Trials and GALE Extension Study
Ursula M. Schmidt-Erfurth, MD
Long-Term Efficacy of Pegcetacoplan in Patients With Geographic Atrophy
Nathan C. Steinle, MD
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Intravitreal ANX007: Results of the ARCHER Study
Jeffrey S. Heier, MD
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Using New Sialic Acid-Coated Nanoparticles
Carl D. Regillo, MD